KZR
Kezar Life Sciences, Inc.6.30
+0.02+0.32%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
46.14MP/E (TTM)
-Basic EPS (TTM)
-8.44Dividend Yield
0%Recent Filings
8-K
8-K
Loan fully repaid, liens released
Kezar Life Sciences repaid its $6.3 million loan in full on October 20, 2025, terminating the 2021 Loan and Security Agreement with Oxford Finance and releasing all related liens. This clears outstanding debt, including interest and exit fees, using cash reserves. Debt-free now. The move strengthens the balance sheet amid biotech funding pressures.
8-K
FDA stalls zetomipzomib; strategic review starts
Kezar Life Sciences disclosed on October 16, 2025, that the FDA canceled a key meeting and demanded a two-year-delaying pharmacokinetics study for zetomipzomib in autoimmune hepatitis, halting its registrational trial plans despite positive PORTOLA data. The company is now exploring strategic alternatives with TD Cowen to maximize shareholder value, implementing workforce reductions for cash conservation, while holding $90.2 million in cash equivalents as of September 30, 2025. It extended its shareholder rights plan to 2026 or 2027 to safeguard the review process. No transaction is assured.
8-K
FDA lifts AIH trial hold
Kezar Life Sciences announced FDA removal of the partial clinical hold on its PORTOLA Phase 2a trial for zetomipzomib in autoimmune hepatitis, paving the way for a Q4 2025 Type C meeting to align on a proposed registration-enabling study. The trial showed 36% of treated patients achieving complete biochemical response with steroid taper, versus none on placebo, alongside a favorable safety profile. Cash reserves stood at $100.8 million as of June 30, 2025, down from $132.2 million year-end, while Q2 net loss narrowed to $13.7 million from $21.5 million. Regulatory uncertainties persist in advancing zetomipzomib.
10-Q
Q2 FY2025 results
Kezar Life Sciences narrowed its operating loss to $14.6 million in Q2 FY2025 ended June 30, 2025, from $23.4 million a year earlier, driven by a 41% drop in research and development expenses to $9.6 million after terminating the PALIZADE trial in lupus nephritis and completing the PORTOLA study in autoimmune hepatitis. Year-to-date, the net loss improved 30% to $30.3 million, with diluted EPS at $(4.14) on 7.3 million shares, reconciling to the weighted average. Cash burn eased, leaving $100.8 million in cash, equivalents, and marketable securities at quarter-end, while repaying $2.6 million in principal on its $7.9 million debt facility maturing November 2026 at ~11% effective rate. Everest collaboration reimbursements offset some costs, but no non-GAAP metrics disclosed in the 10-Q. Yet clinical holds persist. Pivotal AIH data awaits.
IPO
Employees
Sector
Industry
GRI
GRI Bio, Inc.
0.48+0.00
GTBP
GT Biopharma, Inc.
0.72+0.09
KALA
KALA BIO, Inc.
0.56-0.05
KLRS
Kalaris Therapeutics, Inc.
8.66+0.16
KROS
Keros Therapeutics, Inc.
21.53+0.30
KYMR
Kymera Therapeutics, Inc.
84.19-1.49
NKTR
Nektar Therapeutics
49.16-4.14
OMER
Omeros Corporation
8.77-0.43
TLSA
Tiziana Life Sciences Ltd
1.55-0.04
ZVRA
Zevra Therapeutics, Inc.
8.12-0.05